Friction in China's pharmaceutical trade has risen | Import and export in 2017 reached 116.6 billion U.S. dollars

Pharmaceutical Network February 8 hearing Yesterday, the Chinese Chamber of Commerce for Import and Export of Medicines and Health Products announced the export situation of Chinese medicine and health products in 2017, saying that the import and export of Chinese medicinal products amounted to 116.676 billion U.S. dollars, up 12.64% over the same period of last year.

However, in the growth situation, the trade friction suffered by China's pharmaceutical trade has obviously risen, the competition in the new round of international industry has become more fierce, and the affordability of some emerging economies has also been adversely affected. At the same time, the global economy as a whole has shown a recovery The demand for medical and pharmaceutical products in the international market has stabilized and picked up. The pharmaceutical export structure in China has been further optimized, the pace of internationalization of enterprises has been accelerated, new momentum of development has been formed, and the overall development of pharmaceutical trade has been on the rise.

According to statistics of China's customs, the import and export of Chinese medicine and health products in 2017 amounted to 116.676 billion U.S. dollars, up 12.64% over the same period of last year, of which exports were 60.799 billion U.S. dollars, reversing last year's declines of 9.44%, the highest increase in nearly five years On the whole, in 2017, the demand in the international market has risen. The reform in China's supply has achieved initial success. The export volume of medical products has increased at a reduced price and the value of exports Steadily improved. In the meantime, domestic demand still maintained a relatively high level while that of imports maintained a rapid growth.

According to the Chinese Chamber of Commerce for Import and Export of Medicines and Health Products, the export of Chinese medicine rebounded in 2017, with export volume reaching 3.64 billion U.S. dollars, an increase of 2.07% over the same period of last year. The plant extracts market was active with an export volume of 2.01 billion U.S. dollars, up by 4.33% Exports of 250 million US dollars, an increase of 11.03%, Chinese herbal medicines and Pieces exports continued to grow negative, down 2.23%.

At the same time, the export of western medicine also obviously picked up. In 2017, the export of western medicine products in China was 35.456 billion U.S. dollars, up 12.62%, of which, the export of raw material medicines was 29.117 billion U.S. dollars, up 13.71% from the same period of last year. , Backward production capacity gradually withdrawn, and the competitive landscape of high-quality enterprises ushered in a continuous improvement.The export of preparations reached 3.456 billion U.S. dollars, up by 8.32% over the same period of last year.

medical instruments Export is still a steady growth trend. In 2017, the export amount of medical equipment was 21.703 billion U.S. dollars, up by 5.84% over the same period of last year. Among them, medical dressings, disposable consumables, diagnosis and treatment equipment, health rehabilitation equipment and dental equipment all achieved a steady growth Increase 2.97%, 9.53%, 4.11%, 6.29%, 17.00%.

In 2017, pharmaceutical imports continued to show double-digit growth with imports reaching 55.877 billion U.S. dollars, up 16.34% over the same period of last year. Imports of western medicine, the country's top importer of pharmaceutical products, totaled 17.157 billion U.S. dollars, up 21.66% With the import of therapeutic equipment at US $ 14.631 billion, representing an increase of 9.60% as compared with the same period of last year. With the formal implementation of the 'priority evaluation' system in China, imported drugs started to enter the Chinese market together.

In 2017, biomedicine, in vitro diagnostic and other new areas, the Chinese medicine Health products China Import and Export Chamber of Commerce think it is in the ascendant.China's bio-pharmaceutical industry production and marketing scale of steady growth, with an average annual growth rate of 15% or more.China has become second only to the United States, with the largest number of biopharmaceuticals in the country.China's in vitro diagnostic reagents market size In the ever-expanding, it is estimated that by 2019, the market size will reach 72.3 billion yuan, with an annual compound growth rate of 18.7%.

With the overall situation in the export market favorable, trade frictions also gradually increased as the medical service trade enjoyed a booming growth momentum. enterprise In terms of the pharmaceutical industry chain, CRO (Pharmaceutical R & D Contract Outsourcing Service), CMO (Pharmaceutical Manufacturing Contract Outsourcing Service) and CSO (Pharmaceutical Sales Contract Outsourcing Service) have gradually emerged as new industries such as China Pharmaceutical Enterprises to participate in the new form of international division of labor.Chinese medicine service to speed up the 'going out' pace.The data show that China annually sent about 2000 Chinese medicine clinicians, accounting for 60% of the total number of medical personnel assignment.China's more than 60 Chinese medicine service trade institutions in More than 20 countries and regions to start Chinese medicine hospital , Chinese medicine clinics, Chinese medicine health care institutions, traditional Chinese medicine research center, the annual consultation volume reached 250,000 passengers.

Zhang Beibei, deputy director of the legal department of China Chamber of Commerce for Import and Export of Chinese Medicines & Health Products, said that in the frequent cases of trade remedy cases against China, there has been a marked increase in cases of intellectual property cases. In recent years, the trade frictions experienced by China's pharmaceutical industry have shown a clear upward trend. In 2017, China's exports of pharmaceutical products suffered 15 trade friction investigations, including five anti-dumping investigations and one anti-circumvention investigation initiated by India, four U.S. investigations of IP infringement 337 and one antitrust lawsuit initiated by the United States, as well as the EU-initiated 2 cases of anti-dumping investigations and Ukraine launched an anti-dumping investigation.

It is understood that in the past, Chinese enterprises had little experience in patent litigation and few successful cases. Nowadays, the awareness of intellectual property of enterprises is gradually increasing, and their capability of using legal weapons to protect themselves is significantly raised. In 2017, two Chinese pharmaceutical companies Patent Litigation Winning In June, Huahai Pharmaceutical and its US subsidiary, Prinston, won the patent challenge against Noven's 'Brisdelle' paroxetine capsule, the ANDA Challenge Success Story of the PIV Statement for Chinese Pharmaceutical Enterprises In December, Green Leaf Pharmaceutical won the rival rivastigmine single-day patch suit in Germany, and the court upheld the first-instance ruling to determine whether or not the original Novartis patent was valid, and the rivastigmine single-day patch did not infringe the patent.

Regarding the basic trend of the internationalization of the healthcare industry in 2018, the Chinese Chamber of Commerce for Import and Export of Medicines and Health Products believe that as Chinese pharmaceutical enterprises continue to improve their capabilities in international registration and certification, research and development, international marketing and resource mix globally , The pattern of product export and the market pattern of pharmaceutical exports have undergone profound changes, and the international medical and pharmaceutical trade environment has generally been favorable.

Among them, the favorable factors are: the United States, the European Union, India and other major markets demand recovery and is expected to maintain steady growth; preparations, clinics and other products to Europe and the United States market significantly accelerated exports; bulk APIs, medical devices in the global pharmaceutical market rigid Demand has not changed, exports and prices are gradually picking up as the global economy recovers.

At the same time, uncertainties such as South America, Africa and other markets still exist, and the impact of pharmaceutical trade friction can not be ignored. With the implementation of the 13th Five-Year Plan for API Pharmaceutical Industry, China medicine The industry will be more orderly, higher technological content, environmental protection, resource conservation, increase added value, to the downstream extension of the direction, but also conducive to the continued optimization and upgrading of export structure is expected to 2018 steady development of the pharmaceutical industry will continue the fundamentals maintain.